Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Ronan Swords et al.|New England Journal of Medicine|2018Cited by 1.4k
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Jennifer A. Kanakry et al.|Blood|2015Cited by 299
Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I StudyJonathan Webster, Ivana Gojo, Marlise R. Luskin et al.|Blood|2018Cited by 50